BioSpace News Archive

Merck, known as MSD outside the United States and Canada, announced upcoming presentations of new analyses from its HIV clinical development program during the 23rd International AIDS Conference taking place virtually from July 6-10, 2020.

AsclepiX Therapeutics, Inc. announced that it has closed a $35 million Series A financing led by Perceptive Xontogeny Venture Fund with participation from the Perceptive Life Sciences Fund, both funds managed by Perceptive Advisors, and existing investors Rapha Capital Management and Barer & Son Capital.

Applied Genetic Technologies Corporation announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted on June 5.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it received early notification from the U.S. Food and Drug Administration that the company may proceed with initiating a Phase 3, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk hospitalized adults with COVID-19.

IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia.

Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s

Strategic Alliance Combines Yumanity’s Innovative Drug Discovery Platform with Merck’s Development and Commercialization Expertise in Neuroscience

Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer’s Disease program on July 8, 2020 at 8:15 AM ET

Special Edition of Alkermes Inspiration Grants® Program Focused on Addressing Pandemic-Related Needs of People Living with Addiction, Serious Mental Illness, or Cancer

Biohaven Pharmaceutical Holding Company Ltd. reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder.